More evidence for ketoconazole + dutasteride in CRPC

The evidence supporting a role for the combination of dutasteride with ketoconazole as a form of second- or third-line hormone therapy for patients with castration-resistant prostate cancer (CRPC) appears to be increasing. … READ MORE …

Non-ASTRO prostate cancer news reports: Friday, November 6, 2009

In today’s news reports from sources other than the ASTRO meeting, we note items dealing with:

  • PSA bounce in brachytherapy patients
  • Fatal prostate cancer and a history of smoking
  • Ketoconazole + dutasteride in treatment of CRPC … READ MORE …

Satraplatin as second-line chemotherapy for CRPC

Satraplatin is an oral platinum analog that was tested (in combination with prednisone) in a multinational, double-blind, randomized, placebo-controlled, Phase III clinical trial in patients with metastatic castrate-refractory prostate cancer (CRPC) who had progressed after one prior chemotherapy regimen. … READ MORE …

Medivation starts Phase III trial of MDV3100

According to a media release from Medivation, Inc. earlier today, the company has treated the first patient in a Phase III clinical trial of the novel androgen receptor antagonist MDV3100 in advanced prostate cancer. … READ MORE …

Prostate cancer news reports: Wednesday, September 23, 2009

Today’s news reports cover items on:

  • Extent and number of biopsy cores and eligibility for active surveillance
  • Intermittent vs. complete androgen deprivation
  • Hormone therapy and risk for cardiovascular disease and death
  • Surrogate markets for disease progression in men with CRPC … READ MORE …

Takeda to start Phase II trials of TAK-700

According to a media release issued earlier today, Takeda Pharmaceuticals and it’s wholly owned subsidiary, Millennium, are starting the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer. … READ MORE …

Prostate cancer news reports: Wednesday, September 2, 2009

Today’s news reports address:

  • Barbers as prostate risk educators in the black community
  • The need for a Phase III trial of docetaxel + carboplatin in CRPC … READ MORE …

Prostate cancer news reports: Wednesday, August 19

Today’s news reports address:

  • Smoking and risk for prostate cancer
  • Assessing risk for a positive second biopsy after a prior negative biopsy
  • Smoking pot won’t cure your cancer but …
  • Pemetrexed not effective as a single agent in CRPC patients after docetaxel failure … READ MORE …

Another new “vaccine” enters clinical trials

According a media release earlier today, Bellicum Pharmaceuticals, Inc. has announced dosing of their first patient in a Phase I/II clinical trial of “BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer.” … READ MORE …

OncoGenex and development plans for OGX-011

For readers who are interested in OncoGenex Pharmaceuticals‘ plans for the future development of Phase III trial of OGX-011 (an antisense compound that acts as a clusterin growth inhibitor), it’s worth reading Luke Timmerman’s article on Xconomy.com, which is  based on a recent interview with OncoGenex’s CEO, Scott Cormack. … READ MORE …